Jiazheng Cao
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.
Journal: Cancer letters
Published: October 31, 2023
Development and external validation of the multichannel deep learning model based on unenhanced CT for differentiating fat-poor angiomyolipoma from renal cell carcinoma: a two-center retrospective study.
Journal: Journal of cancer research and clinical oncology
Published: July 24, 2023
A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3-rearranged renal cell carcinoma.
Journal: Cancer medicine
Published: June 25, 2023
Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma.
Journal: Journal of translational medicine
Published: February 27, 2023
Hsa_circ_0057105 modulates a balance of epithelial-mesenchymal transition and ferroptosis vulnerability in renal cell carcinoma.
Journal: Clinical and translational medicine
Published: January 27, 2023
Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma.
Journal: Translational andrology and urology
Published: December 16, 2022
Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving overall survival and cancer-specific survival among muscle invasive bladder cancer patients who undergo radical cystectomy: a retrospective cohort study based on SEER database.
Journal: Translational andrology and urology
Published: December 01, 2022
Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer.
Journal: Journal of inflammation research
Published: November 24, 2022
Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 13, 2022
DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC.
Journal: Current cancer drug targets
Published: January 02, 2021
Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer.
Journal: Frontiers in cell and developmental biology
Published: December 28, 2020
Last Updated: 09/26/2026